Meanwhile, a significant increase in Granzyme B+ CD8+ T cells was seen in the PLX-NP-P-aPD-1@Gel group compared with all other treatment groups, indicating an enhanced effector T cell population for stronger anti-tumor effects (Fig. 4e). Here, CD8A is linked to neoplasm.